I ACCEPT PAYPAL SHIPPING: Europe delivered time is 8 — 12 business days.
Usa/canada delivered time 15-20 business days.
Australia/Asia delivered time 15-26 business days.
For any possible questions, please, contact me! NEW 100 % ORIGINAL TRACKING NUMBER THANK YOU FOR VISITING MY LOT It is very important !!! Item will be shipped from Russia for 2-3 days and free shipping takes 14 to 21 days
NEW 100 % ORIGINAL
THANK YOU FOR VISITING MY LOT
Pharmacodynamics Antiviral drug. In preclinical and clinical studies, the effectiveness of the preparation Ingavirin® against influenza viruses of type A (A(H1N1), including «pig» a(H1N1)pdm09, A(H3N2), A(H5N1)) and type B, adenovirus, parainfluenza virus, respiratory syncytial virus; in preclinical studies: corona virus, metapneumovirus, enteroviruses, including Coxsackie virus and Rhino virus. Ingavirin® contributes to accelerated virus elimination, shortening the duration of the disease, and reducing the risk of complications. The mechanism of action is implemented at the level of infected cells due to the stimulation of innate immune factors suppressed by viral proteins. In experimental studies, in particular, it has been shown that the drug Ingavi-Rin® increases the expression of the interferon receptor of the first type IFNAR on the surface of epithelial and immunocompetent cells. An increase in the density of interferon receptors leads to an increase in the sensitivity of cells to endogenous interferon signals. The process is accompanied by activation (phosphorylation) of the STAT1 transmitter protein, which transmits a signal to the cell nucleus for the induction of antiviral genes. It is shown that in the conditions of infection, the drug stimulates the production of antiviral effector protein MHA, which inhibits the intracellular transport of ribonucleoproteins of various viruses, slowing down the process of viral replication. The drug Ingavirin® causes an increase in the content of interferon in the blood to the physiological norm, stimulates and normalizes the reduced ?- interferon producing ability of white blood cells, stimulates ?- interferon-producing ability of white blood cells. It causes the generation of cytotoxic lymphocytes and increases the content of NK-T cells that have high killer activity in relation to virus-infected cells. The anti-inflammatory effect is due to the suppression of the production of key Pro-inflammatory cytokines (tumor necrosis factor (TNF -?), interleukins (IL-1? and IL-6)), a decrease in myeloperoxidase activity. In experimental studies, it has been shown that the combined use of the drug Ingavirin® with antibiotics increases the effectiveness of therapy on a model of bacterial sepsis, including that caused by penicillin-resistant strains of Staphylococcus. Experimental Toxicological studies show a low level of toxicity and a high safety profile of the drug. According to the parameters of acute toxicity, Ingavirin® belongs to the 4th class of toxicity — «low-Toxic substances» (when determining LD50 in experiments on acute toxicity, lethal doses of the drug could not be determined). The drug does not have mutagenic, immunotoxic, allergizing and carcinogenic properties, does not have a local irritating effect. The drug Ingavirin®does not affect the reproductive function, does not have an embryotoxic and teratogenic effect. Pharmacokinetics Absorption and distribution. In an experiment using a radioactive label, it was found that the drug quickly enters the blood from the gastrointestinal tract. It is evenly distributed throughout the internal organs. Maximum concentrations in blood, plasma and most organs are reached 30 minutes after administration of the drug. The AUC values (the area under the pharmacokinetic curve «concentration-time») of the kidneys, liver and lungs slightly exceed the blood AUC (43.77 mcg.h / d). The AUC values for the spleen, adrenal glands, lymph nodes, and thymus are lower than the blood AUC. MRT (average retention time of the drug) in the blood — 37.2 hours. During the course of taking the drug once a day, it accumulates in internal organs and tissues. At the same time, the qualitative characteristics of the pharmacokinetic curves after each administration of the drug were identical: a rapid increase in the concentration of the drug after each administration in 0.5-1 hour after administration and then a slow decrease by 24 hours.
Dosage Inside. Regardless of the meal. In children from 3 to 6 years old who have difficulty swallowing the capsule, it is allowed to dilute the contents of the capsule in water or Apple juice. To do this, carefully open the capsule over a container with a small amount (50-70 ml) of boiled water or Apple juice at room temperature, pour the contents of the capsule into the water or juice, stir the mixture for 20 seconds and drink it whole. You can add sugar. The mixture should be prepared immediately before use; the finished mixture should not be stored. For the treatment and prevention of influenza and acute respiratory viral infections, adults are prescribed 90 mg 1 time a day, children from 7 years-60 mg 1 time a day, children from 3 to 6 years-30 mg 1 time a day. Duration of treatment of influenza and acute respiratory viral infections in adults and children from 7 years — 5-7 days (depending on the severity of the condition). Duration of treatment of influenza and acute respiratory viral infections in children from 3 to 6 years — 5 days. Taking the drug begins from the moment of the first symptoms of the disease, preferably no later than 2 days from the beginning of the disease. To prevent influenza and acute respiratory viral infections after contact with sick persons, adults and children from 7 years of age are prescribed the drug for 7 days, children from 3 to 6 years — for 5 days. If after 5 days of treatment there is no improvement, or the symptoms worsen, or new symptoms appear, you should consult your doctor. Use the drug only according to the indications, the method of use and in the doses specified in the instructions.